A Study of Olaparib and Durvalumab in Prostate Cancer

NCT03810105 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Due to low accrual

Conditions

Prostate Cancer

Interventions

DRUG: Olaparib
DRUG: Durvalumab

Sponsor

Memorial Sloan Kettering Cancer Center